Company news
Aptevo Therapeutics Inc. (NASDAQ:APVO) news
Aptevo Therapeutics Inc. news releases on 6ix. Latest, Apr 15, 2024: Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
Press releases — page 2
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
April 14, 2024
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
April 10, 2024
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
March 4, 2024
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
March 3, 2024
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
November 13, 2023
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
August 9, 2023
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
August 3, 2023
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
July 31, 2023
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
July 17, 2023
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
May 10, 2023
Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update
March 29, 2023
Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding
March 29, 2023
Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors
January 8, 2023
Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 9, 2022
Aptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
November 2, 2022
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
June 8, 2022
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
March 28, 2022
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
March 23, 2022
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
February 8, 2022
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
November 14, 2021
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
November 11, 2021
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
November 10, 2021
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
August 16, 2021
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
August 11, 2021
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
June 28, 2021
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
May 26, 2021
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
May 10, 2021
Aptevo Therapeutics Reports 2020 Financial Results and Provides Business Update
March 30, 2021
Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial
January 10, 2021
Aptevo Therapeutics Announces the Launch of Its Second Platform Technology ADAPTIR-FLEX(TM) and Introduces the New Bispecific Prostate Cancer Candidate APVO442
December 1, 2020
Aptevo Therapeutics Reports Third Quarter Financial Results and Provides Business Update
November 9, 2020
Aptevo Therapeutics Announces Second Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
November 8, 2020
Aptevo Therapeutics Adopts Limited Duration Stockholder Rights Plan
November 7, 2020
Aptevo Therapeutics Announces First Complete Remission in Ongoing APVO436 Phase 1 Clinical Trial
November 2, 2020
Aptevo Therapeutics Reports Second Quarter 2020 Financial Results
August 13, 2020
Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust
August 5, 2020
Aptevo Therapeutics Collects $750,000 Working Capital Escrow From Medexus Related to IXINITY(R) Sale
June 28, 2020
Aptevo Therapeutics Reports First Quarter 2020 Financial Results
May 12, 2020
Aptevo Therapeutics Regains Compliance With Nasdaq Listing Requirements
April 13, 2020
Aptevo Therapeutics Reports 2019 Financial Results and Provides Business Update
March 24, 2020
Aptevo Therapeutics Provides Update On Ongoing APVO436 Phase 1 Clinical Trial
March 15, 2020
Aptevo Therapeutics Doses First Patient in IXINITY Clinical Trial for Potential Pediatric Label Expansion
January 29, 2020
Aptevo Therapeutics Receives Orphan Drug Designation for APVO436 for the Treatment of Acute Myelogenous Leukemia
December 5, 2019
Aptevo Therapeutics Reports Third Quarter 2019 Financial Results
November 6, 2019
Aptevo Therapeutics Introduces New Adaptir™ Bispecific Antibody Candidate Intended for the Treatment of Solid Tumors
September 18, 2019
Aptevo Therapeutics Reports IXINITY® and Pipeline Progress
April 14, 2019